US2011262475A1PendingUtilityA1
Lyme disease vaccine
Est. expiryMay 2, 2028(~1.8 yrs left)· nominal 20-yr term from priority
G01N 33/56911C07K 14/001C07K 16/1207C07K 14/20G01N 2469/20A61P 37/04G01N 2333/20C07K 2319/21A61K 39/0225C07K 2319/00A61P 31/04A61K 39/00Y02A50/30
53
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Antigenic polypeptides comprising linear immunodominant epitopes of Borrelia outer surface protein A (OspA) or Borrelia outer surface protein C (OspC) are useful as vaccines against Lyme disease, and as diagnostics for detecting Borrelia infections. The OspA and OspC antigenic polypeptides typically comprise a plurality of peptides representing epitope containing regions from multiple distinct phyletic groups. The antigenic polypeptides may also include epitopes from both Borrelia OspA and Borrelia OspC.
Claims
exact text as granted — not AI-modified1 . An isolated recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein A (OspA), said at least one linear epitope having an amino acid sequence selected from the group consisting of:
(SEQ ID NO: 1)
STLTITVNSKKTKDLVFTKE;
(SEQ ID NO: 2)
STLTIIVDSKNKTKLVFTKQ
(SEQ ID NO: 3)
STLTISKNRTKTKQLVFTKE
(SEQ ID NO: 4)
STLTISANSKKTKDLVFLTN
(SEQ ID NO: 5)
STLTITVNNKKTKALVFTKQ
(SEQ ID NO: 6)
STLTISVNSKKTTQLVFTKQ
(SEQ ID NO: 7)
STLTISVNSKKTKNIVFTKE
(SEQ ID NO: 8)
STLTISVNSQKTKNLVFTKE
(SEQ ID NO: 9)
NTLTVSADSKKIKDFVFLTD
(SEQ ID NO: 10)
STLTISKNSQKTKQLVFTKE
(SEQ ID NO: 11)
STLTISAKNKKTKDLVFTKQ
(SEQ ID NO: 12)
STLKISKNSKKTKQLVFTKE
(SEQ ID NO: 13)
STLTISAKSKKTKDLVFTKQ
(SEQ ID NO: 14)
STLTISANNKKTKDLVFTKQ
(SEQ ID NO: 15)
KTLTVSADSKKIKDFVFLTD
(SEQ ID NO: 16)
STLTISAKNKKTTDLVFTKQ
(SEQ ID NO: 17)
STLTISKNSRKTKQLVFTKE;
(SEQ ID NO: 18)
STLTISVNSRKTKNLVFTKE;
(SEQ ID NO: 19)
CKQNVSSLDEKNSVSVDLPGEMKVLVSKEKNKDGKYDLIATVDKLELK
GTS;
(SEQ ID NO: 20)
CKQNVSSLDEKNSVSVDLPGGMTVLVSKEKDKDGKYSLEATVDKLELK
GTS;
(SEQ ID NO: 21)
CKQNVSSLDEKNSASVDLPGEMKVLVSKEKDKDGKYSLKATVDKIELK
GTS;
(SEQ ID NO: 22)
LGQTTLEVFKEDGKTLVSKKVTSKDKSSTEEKFNEKGEVSEKLITRAD
GTR;
(SEQ ID NO: 23)
LSQTKFEIFKEDGKTLVSKKVTLKDKSSTEEKFNEKGETSEKTIVRAN
GTR;
(SEQ ID NO: 24)
LSKPTFELFKGDGETLVSRKVSSKDKTSTDEMFNEKGELSAKTMTREN
GTK;
(SEQ ID NO: 25)
KSSTEEKFNEKGEVSEKIITRADGTRLEYTGIKSDSGKAKEVLKGYVL
EG;
(SEQ ID NO: 26)
KSSTEEKFNEKGETSEKTIVRANGTRLEYTDIKSDGSGKAKEVLKDFT
LEG;
and
(SEQ ID NO: 27)
KTSTDEMFNEKGELSAKTMTRENGTKLEYTEMKSDGTGKAKEVLKNFT
LEG.
2 . The isolated recombinant or synthetic peptide or polypeptide of claim 1 , wherein said at least one linear epitope is selected from the group consisting of
STLTITVNSKKTKDLVFTKE;
(SEQ ID NO: 1)
STLTIIVDSKNKTKLVFTKQ;
(SEQ 1D NO: 2)
STLTISKNRTKTKQLVFTKE;
(SEQ ID NO: 3)
STLTISANSKKTKDLVFLTN;
(SEQ ID NO: 4)
STLTITVNNKKTKALVFTKQ;
(SEQ ID NO: 5)
STLTISVNSKKTTQLVFTKQ;
(SEQ ID NO: 6)
STLTISVNSKKTKNIVFTKE;
(SEQ ID NO: 7)
STLTISVNSQKTKNLVFTKE;
(SEQ ID NO: 8)
NTLTVSADSKKIKDFVFLTD;
(SEQ ID NO: 9)
STLTISKNSQKTKQLVFTKE;
(SEQ ID NO: 10)
STLTISAKNKKTKDLVFTKQ;
(SEQ ID NO: 11)
STLKISKNSKKTKQLVFTKE;
(SEQ ID NO: 12)
STLTISAKSKKTKDLVFTKQ;
(SEQ ID NO: 13)
STLTISANNKKTKDLVFTKQ;
(SEQ ID NO: 14)
KTLTVSADSKKIKDFVFLTD;
(SEQ ID NO: 15)
STLTISAKNKKTTDLVFTKQ;
(SEQ ID NO: 16)
STLTISKNSRKTKQLVFTKE;
(SEQ ID NO: 17)
and
STLTISVNSRKTKNLVFTKE.
(SEQ ID NO: 18)
3 . The isolated recombinant or synthetic peptide or polypeptide of claim 1 , further comprising one or more amino acid sequences that are epitopes of Borrelia outer surface protein C (OspC).
4 . The isolated recombinant or synthetic peptide or polypeptide of claim 3 , wherein said one or more amino acid sequences that are epitopes of Borrelia OspC are from an OspC loop 5 region or an OspC alpha helix 5 region, or both.
5 . The isolated recombinant or synthetic peptide or polypeptide of claim 3 , wherein said one or more amino acid sequences that are epitopes of OspC are from OspC types selected from the group consisting of Smar, PLi, H13, PFiM, SL10, PMit, PKi, Pbes, HT22, Pko, PLj7, VS461, DK15, HT25, A,72a, F, E, M, D, U, I, L, H, Szid, PHez, PWa, B, K, N, and C.
6 . The isolated recombinant or synthetic peptide or polypeptide of claim 3 , wherein said one or more amino acid sequences that are epitopes of Borrelia OspC are selected from the group of polypeptides having sequences as set forth in SEQ ID NOS: 65-73.
7 . A method for eliciting an immune response against Borrelia in an individual in need thereof, comprising the step of
administering to said individual an isolated recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein A (OspA), said at least one linear epitope having an amino acid sequence selected from the group consisting of:
(SEQ ID NO: 1)
STLTITVNSKKTKDLVFTKE;
(SEQ ID NO: 2)
STLTIIVDSKNKTKLVFTKQ;
(SEQ ID NO: 3)
STLTISKNRTKTKQLVFTKE;
(SEQ ID NO: 4)
STLTISANSKKTKDLVFLTN;
(SEQ ID NO: 5)
STLTITVNNKKTKALVFTKQ;
(SEQ ID NO: 6)
STLTISVNSKKTTQLVFTKQ;
(SEQ ID NO: 7)
STLTISVNSKKTKNIVFTKE;
(SEQ ID NO: 8)
STLTISVNSQKTKNLVFTKE;
(SEQ ID NO: 9)
NTLTVSADSKKIKDFVFLTD;
(SEQ ID NO: 10)
STLTISKNSQKTKQLVFTKE;
(SEQ ID NO: 11)
STLTISAKSKKTKDLVFTKQ;
(SEQ ID NO: 12)
STLKISKNSKKTKQLVFTKE;
(SEQ ID NO: 13)
STLTISAKSKKTKDLVFTKQ;
(SEQ ID NO: 14)
STLTISANNKKTKDLVFTKQ;
(SEQ ID NO: 15)
KTLTVSADSKKIKDFVFLTD;
(SEQ ID NO: 16)
STLTISAKNKKTTDLVFTKQ;
(SEQ ID NO: 17)
STLTISKNSRKTKQLVFTKE;
(SEQ ID NO: 18)
STLTISVNSRKTKNLVFTKE;
(SEQ ID NO: 19)
CKQNVSSLDEKNSVSVDLPGEMKVLVSKEKNKDGKYDLIATVDKLELK
GTS;
(SEQ ID NO: 20)
CKQNVSSLDEKNSVSVDLPGGMTVLVSKEKDKDGKYSLEATVDKLELK
GTS;
(SEQ ID NO: 21)
CKQNVSSLDEKNSASVDLPGEMKVLVSKEKDKDGKYSLKATVDKIELK
GTS;
(SEQ ID NO: 22)
LGQTTLEVFKEDGKTLVSKKVTSKDKSSTEEKFNEKGEVSEKIITRAD
GTR;
(SEQ ID NO: 23)
LSQTKFEIFKEDGKTLVSKKVTLKDKSSTEEKENEKGETSEKTIVRAN
GTR;
(SEQ ID NO: 24)
LSKPTFELFKGDGETLVSRKVSSKDKTSTDEMFNEKGELSAKTMTREN
GTK;
(SEQ ID NO: 25)
KSSTEEKFNEKGEVSEKIITRADGTRLEYTGIKSDGSGKAKEVLKGYV
LEG;
(SEQ ID NO: 26)
KSSTEEKFNEKGETSEKTIVRANGTRLEYTDIKSDGSGKAKEVLKDFT
LEG;
and
(SEQ ID NO: 27)
KTSTDEMFNEKGELSAKTMTRENGTKLEYTEMKSDGTGKAKEVLKNFT
LEG.
8 . The method of claim 7 , wherein said at least one linear epitope has an amino acid sequence selected from the group consisting of
STLTITVNSKKTKDLVFTKE;
(SEQ ID NO: 1)
STLTIIVDSKNKTKLVFTKQ;
(SEQ ID NO: 2)
STLTISKNRTKTKQLVFTKE;
(SEQ ID NO: 3)
STLTISANSKKTKDLVFLTN;
(SEQ ID NO: 4)
STLTITVNNKKTKALVFTKQ;
(SEQ ID NO: 5)
STLTISVNSKKTTQLVFIKQ;
(SEQ ID NO: 6)
STLTISVNSKKTKNIVFTKE;
(SEQ ID NO: 7)
STLTISVNSQKTKNLVFTKE;
(SEQ ID NO: 8)
NTLTVSADSKKIKDFVFLTD;
(SEQ ID NO: 9)
STLTISKNSQKTKQLVFTKE;
(SEQ ID NO: 10)
STLTISAKSKKTKDLVFTKQ;
(SEQ ID NO: 11)
STLKISKNSKKTKQLVFTKE;
(SEQ ID NO: 12)
STLTISAKSKKTKDLVFTKQ;
(SEQ ID NO: 13)
STLTISANNKKTKDLVFIKQ;
(SEQ ID NO: 14)
KTLTVSADSKKIKDFVFLTD;
(SEQ ID NO: 15)
STLTISAKNKKTTDLVFTKQ;
(SEQ ID NO: 16)
STLTISKNSRKTKQLVFTKE;
(SEQ ID NO: 17)
and
STLTISVNSRKTKNLVFTKE.
(SEQ ID NO: 18)
9 . The method of claim 7 , wherein said isolated recombinant or synthetic peptide or polypeptide further comprises one or more epitopes of Borrelia outer surface protein C (OspC).
10 . The method of claim 9 , wherein said one or more amino acid sequences that are epitopes of Borrelia OspC are selected from the group of polypeptides having sequences as set forth in SEQ ID NOS: 65-73.
11 . A method for ascertaining whether an individual has been exposed to or infected with Borrelia , or both, comprising the steps of
obtaining a biological sample from said individual, exposing said biological sample to a recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein A (OspA), said at least one linear epitope having an amino acid sequence selected from the group consisting of:
(SEQ ID NO: 1)
STLTITVNSKKTKDLVFTKE;
(SEQ ID NO: 2)
STLTIIVDSKNKTKLVFTKQ;
(SEQ ID NO: 3)
STLTISKNRTKTKQLVFTKE;
(SEQ ID NO: 4)
STLTISANSKKTKDLVFLTN;
(SEQ ID NO: 5)
STLTITVNNKKTKALVFTKQ;
(SEQ ID NO: 6)
STLTISVNSKKTTQLVFTKQ;
(SEQ ID NO: 7)
STLTISVNSKKTKNIVFTKE;
(SEQ ID NO: 8)
STLTISVNSQKTKNLVFTKE;
(SEQ ID NO: 9)
NTLTVSADSKKIKDFVFLTD;
(SEQ ID NO: 10)
STLTISKNSQKTKQLVFTKE;
(SEQ ID NO: 11)
STLTISAKNKKTKDLVFTKQ;
(SEQ ID NO: 12)
STLKISKNSKKTKQLVFTKE;
(SEQ ID NO: 13)
STLTISAKSKKTKDLVFTKQ;
(SEQ ID NO: 14)
STLTISANNKKTKDLVFTKQ;
(SEQ ID NO: 15)
KTLTVSADSKKIKDFVFLTD;
(SEQ ID NO: 16)
STLTISAKNKKTTDLVFTKQ;
(SEQ ID NO: 17)
STLTISKNSRKTKQLVFTKE;
(SEQ ID NO: 18)
STLTISVNSRKTKNLVFTKE;
(SEQ 1D NO: 19)
CKQNVSSLDEKNSVSVDLPGEMKVLVSKEKNKDGKYDLIATVDKLELK
GTS;
(SEQ ID NO: 20)
CKQNVSSLDEKNSVSVDLPGGMTVLVSKEKDKDGKYSLEATVDKLELK
GTS;
(SEQ ID NO: 21)
CKQNVSSLDEKNSASVDLPGEMKVLVSKEKDKDGKYSLKATVDKIELK
GTS;
(SEQ ID NO: 22)
LGQTTLEVFKEDGKTLVSKKVTSKDKSSTEEKFNEKGEVSEKIITRAD
GTR;
(SEQ ID NO: 23)
LSQTKFEIFKEDGKTLVSKKVTLKDKSSTEEKFNEKGETSEKTIVRAN
GTR;
(SEQ ID NO: 24)
LSKPTFELFKGDGETLVSRKVSSKDKTSTDEMFNEKGELSAKTMTREN
GTK;
(SEQ ID NO: 25)
KSSTEEKFNEKGEVSEKIITRADGTRLEYTG1KSDGSGKAKEVLKGYV
LEG;
(SEQ ID NO: 26)
KSSTEEKFNEKGETSEKTIVRANGTRLEYTDIKSDGSGKAKEVLKDFT
LEG;
and
(SEQ ID NO: 27)
KTSTDEMFNEKGELSAKTMTRENGTKLEYTEMKSDGTGKAKEVLKNFT
LEG.
and
determining whether antibodies in said biological sample bind to said recombinant or synthetic peptide or polypeptide, wherein detection of antibody binding is indicative of prior exposure to or infection with Borrelia.
12 . The method of claim 11 , wherein said recombinant or synthetic peptide or polypeptide further comprises one or more epitopes of Borrelia outer surface protein C (OspC).
13 . The method of claim 12 , wherein said one or more amino acid sequences that are epitopes of Borrelia OspC are selected from the group of polypeptides having sequences as set forth in SEQ ID NOS: 65-73.
14 . An antibody to a recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein A (OspA), said at least one linear epitope having an amino acid sequence selected from the group consisting of:
(SEQ ID NO: 1)
STLTITVNSKKTKDLVFTKE;
(SEQ ID NO: 2)
STLTIIVDSKNKTKLVFTKQ;
(SEQ ID NO: 3)
STLTISKNRTKTKQLVFTKE;
(SEQ ID NO: 4)
STLTISANSKKTKDLVFLTN;
(SEQ ID NO: 5)
STLTITVNNKKTKALVFTKQ;
(SEQ ID NO: 6)
STLTISVNSKKITQLVFTKQ;
(SEQ ID NO: 7)
STLTISVNSKKTKNIVFTKE;
(SEQ ID NO: 8)
STLTISVNSQKTKNLVFTKE;
(SEQ ID NO: 9)
NTLTVSADSKKIKDFVFLTD;
(SEQ ID NO: 10)
STLTISKNSQKTKQLVFTKE;
(SEQ ID NO: 11)
STLTISAKNKKTKDLVFTKQ;
(SEQ ID NO: 12)
STLKISKNSKKTKQLVFTKE;
(SEQ ID NO: 13)
STLTISAKSKKTKDLVFTKQ;
(SEQ ID NO: 14)
STLTISAKNKKTKDLVFTKQ;
(SEQ ID NO: 15)
KTLTVSADSKKIKDFVFLTD;
(SEQ ID NO: 16)
STLTISAKNKKTTDLVFTKQ;
(SEQ ID NO: 17)
STLTISKNSRKTKQLVFTKE;
(SEQ ID NO: 18)
STLTISVNSRKTKNLVFTKE;
(SEQ ID NO: 19)
CKQNVSSLDEKNSVSVDLPGEMKVLVSKEKNKDGKYDLIATVDKLELK
GTS;
(SEQ ID NO: 20)
CKQNVSSLDEKNSVSVDLPGGMTVLVSKEKDKDGKYSLEATVDKLELK
GTS;
(SEQ ID NO: 21)
CKQNVSSLDEKNSASVDLPGEMKVLVSKEKDKDGKYSLKATVDKIELK
GTS;
(SEQ ID NO: 22)
LGQTTLEVFKEDGKTLVSKKVTSKDKSSTEEKFNEKGEVSEKIITRAD
GTR;
(SEQ ID NO: 23)
LSQTKFETFREDGKTLVSKKVTLKDKSSTEEKFNEKGETSEKTIVRAN
GTR;
(SEQ ID NO: 24)
LSKPTFELFKGDGETLVSRKVSSKDKTSTDEMFNEKGELSAKTMTREN
GTK;
(SEQ ID NO: 25)
KSSTEEKFNEKGEVSEKIITRADGTRLEYTGIKSDGSGKAKEVLKGYV
LEG;
(SEQ ID NO: 26)
KSSTEEKFNEKGETSEKTIVRANGTRLEYTDIKSDGSGKAKEVLKDFT
LEG;
and
(SEQ ID NO: 27)
KTSTDEMFNEKGELSAKTMTRENGTKLEYTEMKSDGTGKAKEVLKNFT
LEG.
15 . The antibody of claim 19 , wherein said antibody is bactericidal for Borrelia spirochetes.
16 . An isolated recombinant or synthetic peptide or polypeptide comprising one or more epitopes from Borrelia outer surface protein A (OspA), said one or more epitopes being from an antigenic region selected from the group consisting of: antigenic region 221-240, antigenic region 17-67, antigenic region 94-144, and antigenic region 119-169.
17 . The isolated recombinant or synthetic peptide or polypeptide of claim 16 , further comprising one or more epitopes of Borrelia outer surface protein C (OspC).
18 . An isolated recombinant or synthetic peptide or polypeptide comprising at least one linear epitope from Borrelia outer surface protein C (OspC), said at least one linear epitope having an amino acid sequence selected from the group consisting of:
i)
(SEQ ID NO: 65)
SETFTNKLKEKHTDLGKEGVTDADAKEAILKTNGTKTKGAEELGKLFE
SVEVLSKAAKEMLANSVKELTSSEEFSTKLKDNHAQLGIQGVTDENAK
KAILKANAAGKDKGVEELEKLSGSLESLSSEDFTKKLEGEHAQLGIEN
VTDENAKKAILITDAAKDKGAAELEKLFKAVENLAAKLKGEHTDLGKE
GVTDDNAKKAILKTNNDKTKGADELEKLFESVKNLSKAAKEMLTNSSE
KFAGKLKNEHASLGKKDATDDDAKKAILKTHGNTDKGAKELKDLSDSV
ESLVSDDFTKKLQSSHAQLGVAGGATTDEEAKKAILRTNAIKDKGADE
LEKLFKSVESLAKAAQDALANSVNELTSKKLKEKHTDLGKKDATDVHA
KEAILKTNGTKDKGAAELEKLFESVENLAKAAKEMLSNSNKAFTDKLK
SSHAELGIANGAATDANAKAAILKTNGTKDKGAQELEKLFESVKNLSK
AAQETLNNSSESFTKKLSDNQAELGIENATDDNAKKAILKTHNAKDKG
AEELVKLSESVAGLLKAAQAILANSVKELTSPVVAESPKKP;
ii)
(SEQ ID NO: 66)
SEKFTTKLKDSHAELGIQSVQDDNAKKAILKTHGTKDKGAKELEELFK
SLESLSKAAQAALTNSVKELTNSDKFTKKLTDSHAQLGAVGGAINDDR
AKEAILKTHGTNDKGAKELKELSESVESLAKAAQAALANSSEAFTKKL
KDSNAQLGMQNGAATDAHAKAAILKTDATKDKGATELGELFKSVESLS
KAAQEASVAFTSKLKSSNAQLGVANGNATDDDAKKAILKTNTPNDKGA
KELKELFESVESLAKAAQAALVNSVQELTNSEAFTNRLKGSHAQLGVA
AATDDHAKEAILKSNPTKDKGAKELKDLSESVESLAKAAQEALANSVK
ELTNSEAFTKKLKDNNAQLGIQNVQDVEAKKAILKTNGDISKSEAFTN
KLKEKHAELGVNGGDTTDDNAKAAIFKTHPTKDKGVEDLEKLSESVKS
LLKAAQAALSNSAAFTKKLQDGHVDLGKTDVTDDNAKEAILKTNPTKT
KGATELEELFKSVEGLVKAAKEA;
iii)
(SEQ ID NO: 67)
SEEFTNKLKSGHADLGKQDATDDHAKAAILKTHATTDKGAKEFKDLFE
SVEGLLKAAQVALTNSVKELTSKLKGGHAELGLAAATDENAKKAILKT
NGTKDKGAEELEKLFKSVESLAKAAKESLTNSVKELTNTKLRDSHAEL
GIQNVQDDNAKRAILKTHGNKDKGAKELKELSESLEKLSKAAQAALAN
SVQELTSSEAFTNKLKEKTQELAVAAGAATDIDAKKAILKTNRDKDLG
ADERGKLFKSVESLSKAAQEASANSVKELTSSEAFTDKLKNEHASLGK
KDATDDDAKKAILKTNVDKTKGADELIKLSGSLESLSKAAQAILANSE
AFTKKLQDSNADLGKHNATDADSKEAILKTNGTKTKGAKELEELFKSV
ESLSKAAKEALSNSVKELTSSQDFINKLKGGHAELGLVAATDANAKAA
ILKTNGDKTKGADEFEKLFKSVEGLLKAAQEALTNSVKELTSSEAFTK
KLQDSNADLGKHDATDADAKKAILKTDATKDK;
iv)
(SEQ ID NO: 68)
SETFTNKLKEKHTDLGKEGVTKGAEELGKLFESVEVLSKAAKEMLANS
VKELTSSEEFSTKLKDNHAQLGIQGVTKGVEELEKLSGSLESLSSEDF
TKKLEGEHAQLGIENVTAAELEKLFKAVENLAKAAKEMAKLKGEHTDL
GKEGVTKGADELEKLFESVKNLSKAAKEMLTNSKESEKFAGKLKNEHA
SLGKKDATKGAKELKDLSDSVESLVKASDDFTKKLQSSHAQLGVAGGA
TTADELEKLFKSVESLAKAAQDALANSVNELTSKKLKEKHTDLGKKDA
TAAELEKLFESVENLAKAAKEMLSNSNKAFTDKLKSSHAELGIANGAA
TKGAQELEKLFESVKNLSKAAQETLNNSVKESESETKKLSDNQAELGI
ENATKGAEELVKLSESVAGLLKAAQAILANSVKELTSPVVAESPKKP;
v)
(SEQ ID NO: 69)
SEKFTTKLKDSHAELGIQSVQDKGAKELEELFKSLESLSKAAQAALTN
SVKELTNSDKFTKKLTDSHAQLGAVGGAINDKGAKELKELSESVESLA
KAAQAALANSSEAFTKKLKDSNAQLGMQNGAATDKGATELGELFKSVE
SLSKAAQEASVAFTSKLKSSNAQLGVANGNATDKGAKELKELFESVES
LAKAAQAALVNSVQELTNSEAFTNRLKGSHAQLGVAAATDKGAKELKD
LSESVESLAKAAQEALANSVKELTNSEAFTKKLKDNNAQLGIQNVQSE
AFTNKLKEKHAELGVNGGDTTDKGVEDLEKLSESVKSLLKAAQAALSN
SAAFTKKLQDGHVDLGKTDVTTKGATELEELFKSVEGLVKAAKEA;
vi)
(SEQ ID NO: 70)
SEEFTNKLKSGHADLGKQDATKGAKEEKDLFESVEGLLKAAQVALTNS
VKELTSKLKGGHAELGLAAATKGAEELEKLFKSVESLAKAAKESLTNS
VKELTNTKLRDSHAELGIQNVQKGAKELKELSESLEKLSKAAQAALAN
SVQELTSSEAFTNKLKEKTQELAVAAGAATLGADERGKLFKSVESLSK
AAQEASANSVKELTSSEAFTDKLKNEHASLGKKDATKGADELIKLSGS
LESLSKAAQAILANSEAFTKKLQDSNADLGKHNATKGAKELEELFKSV
ESLSKAAKEALSNSVKELTSSQDFINKLKGGHAELGLVAATKGADEFE
KLFKSVEGLLKAAQEALTNSVKELTSSEAFTKKLQDSNADLGKHDAT;
vii)
(SEQ ID NO: 71)
SETFTNKLKEKHTDLGKEGVTKGAEELGKLFESVEVLSKAAKEMLANS
VKELTSKGVEELEKLSGSLESLSNKAFTDKLKSSHAELGIANGAATKK
LKEKHTDLGKKDATKGADELEKLFESVKNLSKAAKEMLTNSKEIAAEL
EKLFKAVENLAKAAKEMAKLKGEHTDLGKEGVTSEEFSTKLKDNHAQL
GIQGVTKGAKELKDLSDSVESLVKAAAELEKLFESVENLAKAAKEMLS
NSSEKFAGKLKNEHASLGKKDATSEDFTKKLEGEHAQLGIENVTKGAQ
ELEKLFESVKNLSKAAQETLNNSVKEADELEKLFKSVESLAKAAQDAL
ANSVNELTSSESFTKKLSDNQAELGIENATSDDFTKKLQSSHAQLGVA
GGATTKGAEELVKLSESVAGLLKAAQAILANSVKELTSPVVAESPKKP;
viii)
(SEQ ID NO: 72)
SEAFTKKLKDSNAQLGMQNGAATDKGAKELEELFKSLESLSKAAQAAL
TNSVKELTNKDKGAKELKELFESVESLAKAAQAALVNSVQELTNSEKF
TTKLKDSHAELGIQSVQSDKFTKKLTDSHAQLGAVGGAINDKGAKELK
ELSESVESLAKAAQAALANSDKGAKELKDLSESVESLAKAAQEALANS
VKELTNSVAFTSKLKSSNAQLGVANGNATSEAFTKKLKDNNAQLGIQN
VQTKGATELEELFKSVEGLVKAAKEADKGVEDLEKLSESVKSLLKAAQ
AALSNSAAFTKKLQDGHVDLGKTDVTSEAFTNRLKGSHAQLGVAAATD
KGATELGELFKSVESLSKAAQEASEAFTNKLKEKHAELGVNGGDTT;
and
ix)
(SEQ ID NO: 73)
SEEFTNKLKSGHADLGKQDATKGAKEFKDLFESVEGLLKAAQVALTNS
VKELTSKEKGAEELEKLFKSVESLAKAAKESLTNSVKELTNSEAFTDK
LKNEHASLGKKDATTKLRDSHAELGIQNVQLGADERGKLFKSVESLSK
AAQEASANSVKELTSKEKGAKELEELFKSVESLSKAAKEALSNSVKEL
TSSEAFTKKLQDSNADLGKHNATSEAFTKKLQDSNADLGKHDATKGAD
EFEKLEKSVEGLLKAAQEALTNSVKELTSELKELSESLEKLSKAAQAA
LANSVQELTSSEAFTNKLKEKTQELAVAAGAATKLKGGHAELGLAAAT
KGADELIKLSGSLESLSKAAQAILANSQDFINKLKGGHAELGLVAAT.
19 . The isolated recombinant or synthetic peptide or polypeptide of claim 18 , further comprising one or more epitopes of Borrelia outer surface protein A (OspA).Join the waitlist — get patent alerts
Track US2011262475A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.